We demonstrate that these inhibitors suppress SLC15A4-mediated endolysosomal TLR and NOD features in a variety of human and mouse immune cells; we offer evidence in their power to suppress inflammation in vivo As well as in scientific options; and we provide insights into their system of action. Our results establish SLC15A4 being a druggable goal